{"protocolSection":{"identificationModule":{"nctId":"NCT05669482","orgStudyIdInfo":{"id":"VS-6766-205"},"organization":{"fullName":"Verastem, Inc.","class":"INDUSTRY"},"briefTitle":"Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer","officialTitle":"A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas","acronym":"RAMP205"},"statusModule":{"statusVerifiedDate":"2025-08","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-03-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-08-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-08-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-12-06","studyFirstSubmitQcDate":"2022-12-19","studyFirstPostDateStruct":{"date":"2022-12-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-08-29","lastUpdatePostDateStruct":{"date":"2025-09-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Verastem, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.","detailedDescription":"This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety, tolerability and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients previously untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC)."},"conditionsModule":{"conditions":["KRAS Activating Mutation","Metastatic Cancer","Pancreas Cancer","Neoplasms Pancreatic","Malignant Neoplasm of Pancreas"],"keywords":["avutometinib (VS-6766)","Metastatic Cancer","KRAS Mutation","Pancreatic Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":40,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Gemcitabine + nab-paclitaxel + avutometinib (VS-6766) + defactinib","type":"EXPERIMENTAL","description":"To determine the recommended phase 2 dose (RP2D) for gemcitabine Gemcitabine + nab-paclitaxel + avutometinib (VS-6766) + defactinib in patients with untreated metastatic PDAC.","interventionNames":["Drug: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel"]},{"label":"Gemcitabine + nab-paclitaxel + avutometinib (VS-6766) + defactinib RP2D","type":"EXPERIMENTAL","description":"To determine the efficacy of the RP2D identified in Part A in untreated metastatic PDAC patients","interventionNames":["Drug: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel"]}],"interventions":[{"type":"DRUG","name":"avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel","description":"The RP2D of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel determined in Part A will be used in Part B dose expansion.","armGroupLabels":["Gemcitabine + nab-paclitaxel + avutometinib (VS-6766) + defactinib","Gemcitabine + nab-paclitaxel + avutometinib (VS-6766) + defactinib RP2D"],"otherNames":["Gemzar","Abraxane"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part A: To determine RP2D for avutometinib (VS-6766) and defactinib in combination gemcitabine and nab-paclitaxel","description":"Assessment of Dose-limiting toxicities (DLTs)","timeFrame":"28 days"},{"measure":"To determine the efficacy of the RP2D identified in Part A","description":"Confirmed overall response rate (ORR) (partial response \\[PR\\] + complete response \\[CR\\] defined according to Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST 1.1\\])","timeFrame":"6 months"}],"secondaryOutcomes":[{"measure":"Duration of Response (DOR)","description":"Time of first response to PD as assessed per RECIST 1.1","timeFrame":"24 months"},{"measure":"Disease Control Rate (DCR)","description":"CR + PR + SD as assessed per RECIST 1.1","timeFrame":"24 months"},{"measure":"Progression Free Survival (PFS)","description":"From the time of first dose of study intervention to PD as assessed per RECIST 1.1 or death from any cause","timeFrame":"24 months"},{"measure":"Overall Survival (OS)","description":"From the time of first dose of study intervention to PD as assessed per RECIST 1.1 or death from any cause","timeFrame":"Up to 5 years"},{"measure":"Plasma Pharmacokinetics (PK) of avutometinib (VS-6766) and Defactinib and relevant metabolites, Tmax","description":"Time to Maximum concentration (Tmax)","timeFrame":"10 weeks"},{"measure":"Plasma Pharmacokinetics (PK) of avutometinib (VS-6766) and Defactinib and relevant metabolites, AUC","description":"Area under plasma Concentration (AUC) 0 to t","timeFrame":"10 Weeks"},{"measure":"Plasma Pharmacokinetics (PK) of avutometinib (VS-6766) and Defactinib and relevant metabolites, Half-life","description":"concentration Half-life (T1/2)","timeFrame":"10 weeks"},{"measure":"Frequency and severity adverse events (AEs) and Serious Adverse Events (SAEs)","description":"Count of AE and SAEs by grade, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grading scale","timeFrame":"24 months"},{"measure":"Number of abnormal laboratory values","description":"Count of abnormal laboratory values by grade","timeFrame":"24 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects ≥ 18 years of age\n* Histologic or cytologic evidence of metastatic pancreatic ductal adenocarcinoma.\n* An Eastern Cooperative Group (ECOG) performance status ≤ 1\n* Measurable disease according to RECIST 1.1\n* Adequate organ function\n* Adequate cardiac function\n* Agreement to use highly effective method of contraceptive\n\nExclusion Criteria:\n\n* Patients with pancreatic neuroendocrine tumors\n* Prior or concomitant treatment for metastatic pancreatic ductal adenocarcinoma\n* Prior treatment with inhibitors of the RAS /MAPK pathway \\[e.g. MEK inhibitors\\] or inhibitors of FAK\n* History of prior malignancy, with the exception of curatively treated malignancies\n* Major surgery within 4 weeks (excluding placement of vascular access)\n* Concurrent heart disease or severe obstructive pulmonary disease\n* Concurrent ocular disorders\n* Active skin disorder that has required systemic therapy within the past 1 year\n* Patients with interstitial lung disease or pulmonary fibrosis or severe lung disease, pulmonary edema, and adult respiratory distress syndrome\n* Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"MD Verastem","affiliation":"Verastem, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"UCSF Helen Diller Family Comprehensive Cancer Center","city":"San Francisco","state":"California","zip":"94158","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"University of Chicago","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"University of Michigan Cancer Center","city":"Ann Arbor","state":"Michigan","zip":"48109","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Washington University School of Medicine","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Laura & Isaac Perlmutter Cancer Center at NYU Langone Health","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"New York Presbyterian/Weill-Cornell Medical Center","city":"New York","state":"New York","zip":"10021","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"University of Pennsylvania","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"University of Utah Huntsman Cancer Institute","city":"Salt Lake City","state":"Utah","zip":"84112","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Virginia Mason Medical Center","city":"Seattle","state":"Washington","zip":"98101","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Fred Hutchinson Cancer Center","city":"Seattle","state":"Washington","zip":"98109","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D009362","term":"Neoplasm Metastasis"},{"id":"D010190","term":"Pancreatic Neoplasms"}],"ancestors":[{"id":"D009385","term":"Neoplastic Processes"},{"id":"D009369","term":"Neoplasms"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D004701","term":"Endocrine Gland Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D010182","term":"Pancreatic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C584510","term":"defactinib"},{"id":"D000093542","term":"Gemcitabine"},{"id":"C520255","term":"130-nm albumin-bound paclitaxel"},{"id":"D000068196","term":"Albumin-Bound Paclitaxel"}],"ancestors":[{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D017239","term":"Paclitaxel"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D000418","term":"Albumins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"}]}},"hasResults":false}